Eloxx Pharmaceuticals (ELOX) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eloxx Pharmaceuticals is the larger company by market cap ($55.5 million vs $54.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELOX | LONA |
|---|---|---|
| Share price | $13.74 | $5.75 |
| Market cap | $55.46M | $54.17M |
| 1-day change | -9.49% | 0.00% |
| YTD return | — | -24.04% |
| 1-year return | — | +45.94% |
| 5-year return | — | -93.99% |
| P/E ratio (TTM) | 3.90 | — |
| EPS (TTM) | $3.52 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.40 | $14.21 |
| 52-week low | $8.20 | $2.21 |
| Distance from 52-week high | -41.28% | -59.54% |
| Analyst consensus | none | none |
| Avg. price target upside | +178.38% | +201.39% |
| Average volume | 44.52K | 185.45K |
| Shares outstanding | 4.04M | 9.42M |
| Employees | 10 | 19 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Eloxx Pharmaceuticals
ELOX stock →Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 19 employees
ELOX vs LONA FAQ
Which is bigger, Eloxx Pharmaceuticals or LeonaBio?
Eloxx Pharmaceuticals (ELOX) is larger, with a market capitalization of $55.46M compared with $54.17M for LeonaBio (LONA).
Are Eloxx Pharmaceuticals and LeonaBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.